Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor

Ajax CEO Martin Vogelbaum (L) and scientific advisory board chair Ross Levine April 27, 2026 08:36 AM EDTUpdated 10:15 AM Deals Lil­ly an­nounces a new can­cer deal, pay­ing Ajax up to $2.3B for JAK in­hibitor Kyle LaHucik Biotech Correspondent Eli Lil­ly keeps putting its GLP-1 wind­fall to use. On Mon­day, the an­ti-obe­si­ty drug­mak­er an­nounced its lat­est deal to ex­pand its pipeline of fu­ture drugs … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER